Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01769222 · OUTCOME

Duration of Response (Phase 2 Only)

Ipilimumab and Local Radiation for Selected Solid Tumors · Source last updated 2024-01-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 5 years

What was measured

Data will be summarized using Kaplan-Meier estimates for time to event data.

Analysis population: This was a study phase 2 outcome, and no participants were enrolled in study phase 2.

Groups in this outcome

Ipilimumab 25 mg

Participants receive ipilimumab intratumorally on Day 1 Ipilimumab: Given intratumorally

Ipilimumab 25 mg and Radiation Therapy

Participants receive ipilimumab intratumorally on Day 1 and undergo local radiation therapy (10 Gy/fraction) within 48 hours for at least 3 fractions Ipilimumab: Given intratumorally Radiation therapy: Undergo local radiation therapy, 10 Gy x 3 fractions

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ipilimumab 25 mg0
Ipilimumab 25 mg and Radiation Therapy0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
description
Data will be summarized using Kaplan-Meier estimates for time to event data.
groups
  1. description
    Participants receive ipilimumab intratumorally on Day 1 Ipilimumab: Given intratumorally
    id
    OG000
    title
    Ipilimumab 25 mg
  2. description
    Participants receive ipilimumab intratumorally on Day 1 and undergo local radiation therapy (10 Gy/fraction) within 48 hours for at least 3 fractions Ipilimumab: Given intratumorally Radiation therapy: Undergo local radiation therapy, 10 Gy x 3 fractions
    id
    OG001
    title
    Ipilimumab 25 mg and Radiation Therapy
population Description
This was a study phase 2 outcome, and no participants were enrolled in study phase 2.
reporting Status
POSTED
time Frame
Up to 5 years
title
Duration of Response (Phase 2 Only)
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice